Procter & Gamble Health Limited's Board has approved the re-appointment of Mr. S. Madhavan as Independent Director for a term of five years effective November 15, 2026. The decision, taken at a Board meeting held on May 26, 2026, follows the recommendation of the company's Nomination & Remuneration Committee. The re-appointment is subject to the approval of the shareholders.

The company confirmed that Mr. Madhavan meets the criteria of independence laid down in Section 149 of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It was further affirmed that he is not debarred or disqualified from holding the office of a Director by any order from SEBI, the Ministry of Corporate Affairs, or any other statutory authority. Additionally, Mr. Madhavan does not hold any shares in the company.

The re-appointment is pursuant to the completion of Mr. Madhavan's first tenure. The company provided the requisite details in compliance with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Re-appointment Details

Procter & Gamble Health Limited reported a 30% rise in Profit After Tax (PAT) to ₹327 crore for the financial year ended March 31, 2026, compared to the comparable 12-month period in the previous year. Revenue from operations for the year stood at ₹1,385 crore, an increase of 16% over the indexed period. The company changed its financial year end from June 30 to March 31, making the previous financial year a nine-month period ending March 31, 2025; consequently, the figures are indexed against a comparable 12-month period from April 1, 2024, to March 31, 2025.

The audited financial results for FY26 were approved by the Board in a meeting held on May 26, 2026. Milind Thatte, Managing Director, attributed the growth to superior innovations backed by science, strengthened go-to-market capabilities, and productivity initiatives.

Q4 Performance

Procter & Gamble Health delivered a strong quarterly performance, with sales rising 20% to ₹365 crore. Profit After Tax for the quarter stood at ₹95 crore, up 55% versus the same period last year, driven by strong brand fundamentals and positive consumer response to new innovations. The quarter also saw a significant improvement in profitability metrics, with EBITDA rising to 1.35b Rupees from 809m Rupees in the same period last year, while EBITDA margin expanded sharply to 36.60% from 26.02% year-on-year.

Full Year Financial Performance

For the full year, the company reported sales of ₹1,385 crore and PAT of ₹327 crore. The performance was driven by a focused portfolio of trusted brands and sustained investment across the value chain.

Dividend Declaration

The Board recommended a final dividend of ₹45 per equity share for the financial year ended March 31, 2026. Considering the interim dividend of ₹160 per share paid on February 27, 2026, the total dividend payout for the fiscal amounts to ₹205 per share. The dividend is subject to approval by shareholders at the ensuing 59th Annual General Meeting.

Product and Community Updates

The company continued to grow its business with new product innovations, including Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. Through its Corporate Social Responsibility initiative, P&G Sehat, the company has impacted over 15 lakh lives by providing healthcare access and awareness in underserved communities.